Oncolytics Biotech annual ebitda
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Oncolytics Biotech EBITDA Growth & History (ONCY)
Oncolytics Biotech's calculated EBITDA was −$34.9M for fiscal 2024.
View full Oncolytics Biotech company overviewOncolytics Biotech annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | −$34.9M | −$1.2M | — |
| 2023 | 2023-12-31 | −$33.7M | −$6.9M | — |
| 2022 | 2022-12-31 | −$26.8M | −$726,000 | — |
| 2021 | 2021-12-31 | −$26.1M | −$735,000 | — |
| 2020 | 2020-12-31 | −$25.4M | −$5.1M | — |
| 2019 | 2019-12-31 | −$20.3M | −$3.1M | — |
| 2018 | 2018-12-31 | −$17.2M | −$1.7M | — |
| 2017 | 2017-12-31 | −$15.5M | −$382,412 | — |
| 2016 | 2016-12-31 | −$15.1M | −$1.4M | — |
| 2015 | 2015-12-31 | −$13.7M | — | — |
Oncolytics Biotech quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Oncolytics Biotech ebitda trends
Over the last five reported fiscal years, Oncolytics Biotech's ebitda decreased from −$20.3M to −$34.9M, a change of −$14.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oncolytics Biotech filings at SEC.gov ↗